ipharmacenter Consulting services

ELI LILLY Eli Lilly's Retevmo Shows Strong Benefit As Adjuvant Therapy In Early RET Fusion-Positive Lung Cancer Eli Lilly has reported positive Phase 3 results from the LIBRETTO 432 trial, which tested Retevmo (selpercatinib) as adjuvant treatment compared with placebo in people with early stage RET fusion positive non small cell lung cancer. The study met its primary goal, with investigator assessed event free survival significantly improved and selpercatinib lowering the ri

Pfizer and Innovent Biologics have formed a broad global partnership aimed at advancing a new generation of oncology therapies, focusing on early-stage and newly discovered cancer treatment candidates. Also read: Top 10 Pharma Companies by Revenue in 2025 The agreement covers the joint development of 12 innovative drug programs, including antibody-drug conjugates (ADCs) featuring novel payload technologies and multispecific antibodies engineered to enhance immune system engag